Christine Fox - 30 Apr 2026 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Reporting relationship: EVP, U.S. Commercial
Issuer ticker: TEVA
Reported as of: 30 Apr 2026
Net transaction value: -$750,620
SEC form: 4
Accepted by SEC: 04 May 2026, 16:00:53 UTC
Prior SEC filing: 09 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Dov Bergwerk as attorney-in-fact for Christine Fox

Key filing fact

Christine Fox filed Form 4 for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) on 04 May 2026.

Key facts

This page summarizes Christine Fox's Form 4 filing for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 04 May 2026, 16:00.

Change

Previous filing in this sequence was filed on 09 Mar 2026.
Current net transaction value: -$750,620.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001998173 Primary reporting owner

Fox Christine

Relationship: EVP, U.S. Commercial
Address: C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 124 DVORA HANEVI'A ST.,, TEL AVIV, ISRAEL
Signature: /s/ Dov Bergwerk as attorney-in-fact for Christine Fox
Signature date: 04 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TEVA transaction

Ordinary Shares

Sale

Transaction value: $750,620
Shares: -21,258
Change %: -25%
Price: $35.31
Shares after: 63,647
Date: 30 Apr 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.28 to $35.33, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.